Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)

Salvatore Maria Corsello; Roberto Salvatori; Agnese Barnabei; Liana De Vecchis; Paolo Marchetti; Francesco Torino

doi:10.1007/s00280-013-2213-y

Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)

Salvatore Maria Corsello
, Roberto Salvatori
, Agnese Barnabei
, Liana De Vecchis
, Paolo Marchetti
, Francesco Torino

Università Cattolica del Sacro Cuore

Johns Hopkins University
IRCCS Istituti fisioterapici ospitalieri - Istituto Regina Elena
University of Rome Tor Vergata
Sant'Andrea Hospital

Risultato della ricerca: Contributo in rivista › Articolo

11 Citazioni (Scopus)

Abstract

With the expanding use of ipilimumab, oncologists are not only faced with most common side effects, such as diarrhea and rush, but also with unusual adverse events, such as certain endocrinopathies. These include hypophysitis (0–17 %), thyroid disease or abnormalities in thyroid function tests (0–2 %), and occasionally primary adrenal insufﬁciency

Lingua originale	Inglese
pagine (da-a)	489-490
Numero di pagine	2
Rivista	Cancer Chemotherapy and Pharmacology
Volume	72
DOI	https://doi.org/10.1007/s00280-013-2213-y
Stato di pubblicazione	Pubblicato - 2013

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

Adrenal Cortex Hormones
Anti-Inflammatory Agents
Antibodies, Monoclonal
Endocrine System Diseases
Humans
Hypopituitarism
Methylprednisolone
Neoplasms
Prednisone
Thyroid Diseases

Accesso al documento

10.1007/s00280-013-2213-y

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{d02e92498c9b4c728ddb7dd9a69eb620,

title = "Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)",

abstract = "With the expanding use of ipilimumab, oncologists are not only faced with most common side effects, such as diarrhea and rush, but also with unusual adverse events, such as certain endocrinopathies. These include hypophysitis (0–17 \%), thyroid disease or abnormalities in thyroid function tests (0–2 \%), and occasionally primary adrenal insufﬁciency",

keywords = "Adrenal Cortex Hormones, Anti-Inflammatory Agents, Antibodies, Monoclonal, Endocrine System Diseases, Humans, Hypopituitarism, Methylprednisolone, Neoplasms, Prednisone, Thyroid Diseases, Adrenal Cortex Hormones, Anti-Inflammatory Agents, Antibodies, Monoclonal, Endocrine System Diseases, Humans, Hypopituitarism, Methylprednisolone, Neoplasms, Prednisone, Thyroid Diseases",

author = "Corsello, \{Salvatore Maria\} and Roberto Salvatori and Agnese Barnabei and \{De Vecchis\}, Liana and Paolo Marchetti and Francesco Torino",

year = "2013",

doi = "10.1007/s00280-013-2213-y",

language = "English",

volume = "72",

pages = "489--490",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

}

TY - JOUR

T1 - Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)

AU - Corsello, Salvatore Maria

AU - Salvatori, Roberto

AU - Barnabei, Agnese

AU - De Vecchis, Liana

AU - Marchetti, Paolo

AU - Torino, Francesco

PY - 2013

Y1 - 2013

N2 - With the expanding use of ipilimumab, oncologists are not only faced with most common side effects, such as diarrhea and rush, but also with unusual adverse events, such as certain endocrinopathies. These include hypophysitis (0–17 %), thyroid disease or abnormalities in thyroid function tests (0–2 %), and occasionally primary adrenal insufﬁciency

AB - With the expanding use of ipilimumab, oncologists are not only faced with most common side effects, such as diarrhea and rush, but also with unusual adverse events, such as certain endocrinopathies. These include hypophysitis (0–17 %), thyroid disease or abnormalities in thyroid function tests (0–2 %), and occasionally primary adrenal insufﬁciency

KW - Adrenal Cortex Hormones

KW - Anti-Inflammatory Agents

KW - Antibodies, Monoclonal

KW - Endocrine System Diseases

KW - Humans

KW - Hypopituitarism

KW - Methylprednisolone

KW - Neoplasms

KW - Prednisone

KW - Thyroid Diseases

KW - Adrenal Cortex Hormones

KW - Anti-Inflammatory Agents

KW - Antibodies, Monoclonal

KW - Endocrine System Diseases

KW - Humans

KW - Hypopituitarism

KW - Methylprednisolone

KW - Neoplasms

KW - Prednisone

KW - Thyroid Diseases

UR - http://hdl.handle.net/10807/52890

U2 - 10.1007/s00280-013-2213-y

DO - 10.1007/s00280-013-2213-y

M3 - Article

SN - 0344-5704

VL - 72

SP - 489

EP - 490

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

ER -

Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo